Skip to content
The Nexus
HEALTHMay 29 · 13:34 UTCSTAT NEWSEd Silverman

STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more

An FDA advisory panel recommended updating fall 2023 Covid vaccines to target the XFG variant. Pfizer and China’s Innovent Biologics announced a $10.5 billion global collaboration to develop 12 early-stage cancer drugs. The WHO fast-tracked three existing drugs for testing against the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
U.S. Food and Drug AdministrationorganizationPfizerorganizationInnovent BiologicsorganizationWorld Health OrganizationorganizationRegeneron PharmaceuticalorganizationMapp BioorganizationGilead SciencesorganizationXFG varianttopicDemocratic Republic of the CongoplaceUgandaplace
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more · The Nexus